Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGEND-D
ISRCTN58098350Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of glibenclamide and dapagliflozin in diabetes mellitus type 1 (T1D) (2 arms), sponsored by University of Oxford. Primary endpoint: Plasma glucagon concentration at 40 minutes during hypoglycaemia. Started Feb 2024; status: completed.
02
Drugs
glibenclamidedapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ISRCTN58098350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58098350.